For sales

📢Highlights from the Week of June 03 – 09, 2025 in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of June 03-09, 2025 The EMA has granted Orphan Drug Designation to Spinogenix’s SPG302, the first therapy aimed at regenerating synapses in patients with ALS Denifanstat (ASC40), Ascletis’s oral FASN inhibitor for acne, meets all primary and secondary Phase 3 trial endpoints, demonstrating up to 178% higher efficacy than standard treatments like sarecycline and doxycycline FDA grants a third approval to Bayer’s NUBEQA for advanced prostate cancer, supported by Phase 3 ARANOTE trial results, enabling its use in mHSPC with ADT, with or without docetaxel ( FDA, Approval ) ( Dermatology, Phase3 ) ( ALS, OrphanDrug, EMA, Rare Disease ) Pg 1/2 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.